<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01919164</url>
  </required_header>
  <id_info>
    <org_study_id>EMR700692_006</org_study_id>
    <secondary_id>2011-003059-20</secondary_id>
    <nct_id>NCT01919164</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin in Participants With Osteoarthritis of the Knee</brief_title>
  <acronym>FORWARD</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel-group Trial to Investigate the Efficacy and Safety of Different Intra Articular (i.a.) Dosages of Sprifermin in Subjects With Primary Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nordic Bioscience A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase 2
      trial of Sprifermin administered intra-articularly in participants with primary
      osteoarthritis of the knee and Kellgren-Lawrence Grade 2 or 3. The trial was intended to
      investigate the efficacy and safety of different intra articular dosages of Sprifermin in
      these individuals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants were equally randomized to either one of 4 treatment arms or a placebo arm. The
      trial consists of a Screening period lasting up to 42 days, a two-year double-blind
      placebo-controlled (DBPC) treatment phase, which begins at randomization (Week 0) and ends at
      Year 2, and a 3-year extended follow-up phase.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 29, 2013</start_date>
  <completion_date type="Actual">May 7, 2019</completion_date>
  <primary_completion_date type="Actual">May 5, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Cartilage Thickness in the Total Femorotibial Joint as Evaluated by Quantitative Magnetic Resonance Imaging (qMRI) at Year 2</measure>
    <time_frame>Baseline, Year 2 (Week 104)</time_frame>
    <description>The change in cartilage thickness at 2 years was calculated based on quantitative magnetic resonance imaging (qMRI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale, Stiffness Subscale, Physical Function Subscale and Total Score at Week 52, Week 78 and Week 104</measure>
    <time_frame>Baseline, Week 52, Week 78 and Week 104</time_frame>
    <description>WOMAC pain subscale consists of 5 questions (Likert Scale) relating to pain. Sum of items of pain subscale ranges from 0-11. Higher scores=worse pain. Stiffness subscale consists of 2 questions relating articular function. Sum of items of stiffness subscale ranges from 0-8. Higher scores=worse function. Physical function subscale consists of 17 question relating to physical activities. Sum of items of physical function subscale ranges from 0-68. Higher scores= worse functional limitations. Each sub-scale is directly transformed into a 0-100 scale, where higher score indicates worse condition. WOMAC total score(24questions) is sum of total subscales which was directly transformed into score range from 0-100. Higher scores=worse condition. Negative value in change is indicative of improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the 20-meter Walk Test at Week 12, 26, 38, 52, 64, 78, 90 and 104</measure>
    <time_frame>Baseline, Week 12, 26, 38, 52, 64, 78, 90 and 104</time_frame>
    <description>The 20-meter walk test is an objective test of physical function which consists of measuring the time needed for the participant to walk 20 meters at a normal pace. A stopwatch was used for time measurement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Patient's Global Assessment (PGA) at Week 12, 26, 38, 52, 64, 78, 90 and 104</measure>
    <time_frame>Baseline, Week 12, 26, 38, 52, 64, 78, 90 and 104</time_frame>
    <description>The Patient Global Assessment is based on participant's answer to the question &quot;Considering all the ways your osteoarthritis of the knee has affected you during the last 48 Hours, select the number that best describes the impact of your knee osteoarthritis on your daily life&quot;, and can take on values between 0-10 (0=None, 10=Extreme), for summaries the values are rescaled to 0-100 by multiplication with 10. Higher scores indicated worsening of condition. A negative value in change in Patient's Global Assessment is indicative of an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Minimal Joint Space Width (mJSW) in the Medial and Lateral Compartments as Evaluated by X-ray at Week 52 and 104</measure>
    <time_frame>Baseline, Week 52 and 104</time_frame>
    <description>Change in joint space narrowing was visualized with the &quot;fixed flexion&quot; knee radiograph. Determination of joint space narrowing by X-ray is considered to be a semi-quantitative method for assessment of progression of knee Osteoarthritis (OA). X-rays of both the target knee and the contralateral knee were performed. X-rays were read centrally. X-ray images were used to measure mJSW in the medial femorotibial and lateral femorotibial compartments and to determine the participant's baseline Kellgren-Lawrence grades (KLG).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cartilage Thickness in the Medial and Lateral Compartments as Well as in the Total Femorotibial Joint</measure>
    <time_frame>Medial and Lateral: Baseline, Week 26, 52, 78 and 104; Total: Baseline, Week 26, 52 and 78</time_frame>
    <description>The change in cartilage thickness was calculated based on quantitative magnetic resonance imaging (qMRI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cartilage-Volume in the Medial and Lateral Compartments as Well as in the Total Femorotibial Joint at Week 26, 52, 78 and 104</measure>
    <time_frame>Baseline, Week 26, 52, 78 and 104</time_frame>
    <description>The change in cartilage volume in the medial and lateral compartments as well as in the total femorotibial joint at Week 26, 52, 78 and 104 was calculated based on qMRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Synovial Fluid Levels of Sprifermin/FGF-18</measure>
    <time_frame>Pre-dose at Week 0, 2 hours post-dose at Week 1 and 2 of Cycle 1, 2, 3 and 4 (each cycle is of 28 days)</time_frame>
    <description>Levels of sprifermin/FGF-18 in synovial fluid were measured to provide a first estimate of the residence time of sprifermin in the synovial fluid.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Levels of Sprifermin/FGF-18</measure>
    <time_frame>Pre-dose at Week 0, 2 hours post-dose at Week 1 and 2 of Cycle 1, 2, 3 and 4 (each cycle is of 28 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">549</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received Placebo matched to Sprifermin as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sprifermin (AS902330) 30 mcg/placebo - 2 Cycles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Sprifermin 30 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sprifermin (AS902330) 30 mcg- 4 Cycles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sprifermin (AS902330) 100 mcg/Placebo (2 cycles)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sprifermin (AS902330) 100 mcg- 4 Cycles</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sprifermin</intervention_name>
    <description>Participants received Sprifermin as intra-articular injection.</description>
    <arm_group_label>Sprifermin (AS902330) 100 mcg- 4 Cycles</arm_group_label>
    <arm_group_label>Sprifermin (AS902330) 100 mcg/Placebo (2 cycles)</arm_group_label>
    <arm_group_label>Sprifermin (AS902330) 30 mcg- 4 Cycles</arm_group_label>
    <arm_group_label>Sprifermin (AS902330) 30 mcg/placebo - 2 Cycles</arm_group_label>
    <other_name>Recombinant Human Fibroblast Growth Factor-18 (rhFGF-18)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants received Placebo matched to sprifermin as intra-articular injection.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sprifermin (AS902330) 100 mcg/Placebo (2 cycles)</arm_group_label>
    <arm_group_label>Sprifermin (AS902330) 30 mcg/placebo - 2 Cycles</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age from 40 to 85 years; of either sex

          -  Primary femorotibial osteoarthritis according to American College of Rheumatology
             (ACR) clinical and radiographic criteria , and meeting protocol-specified X-ray
             criteria in the target knee at screening

          -  Pain score in the target knee and/or the need for regular symptomatic treatment of
             knee pain with paracetamol (acetaminophen), systemic non-steroidal anti-inflammatory
             drugs (NSAIDs) including cyclooxygenase (COX)-2 selective inhibitors (coxibs), or
             tramadol on most days in the previous month (that is, more than half of the days in
             the previous month)

          -  A history of pain due to Osteoarthritis in the target knee for at least 6 months

          -  A protocol-specified pain score for the target knee in response to Question 1 of the
             WOMAC pain index (&quot;how much pain have you had [in the target knee, over the past 48
             hours] when walking on a flat surface?&quot;) after washout of at least 5 half-lives of
             analgesic medication(s): acetaminophen, topical or oral NSAIDS, coxibs, opioids,
             and/or tramadol

          -  Women of childbearing potential must use a form of contraception with a failure rate
             of less than 1 percent per year throughout the trial

        Exclusion Criteria:

          -  Malalignment of greater than 5 degrees in the femorotibial axis of the target knee

          -  Clinical signs of inflammation (redness) in the target knee

          -  Intra-articular administration of corticosteroids or hyaluronic acid into either knee
             within 6 months before Screening

          -  Planned knee surgery (affecting either the target or the contralateral knee) within
             the next two years

          -  Concomitant conditions or treatments deemed to be incompatible with trial
             participation

          -  Any contraindication to MRI according to MRI guidelines, including the inability to
             undergo a knee MRI exam because of inability to fit in the scanner or knee coil

          -  Pregnancy or breastfeeding

          -  Participation in another clinical trial within the 30 days (or 5 half-lives of the
             investigated compound, whichever is longer) before screening

          -  Legal incapacity or limited legal capacity
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible, MD</last_name>
    <role>Study Director</role>
    <affiliation>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Pardubice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Prague</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Ballerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Hong Kong</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=EMR700692_006</url>
    <description>Trial Awareness and Transparency website Scope</description>
  </link>
  <link>
    <url>https://medical.emdserono.com/en_US/home.html</url>
    <description>US Medical Information website, Medical Resources</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 7, 2013</study_first_submitted>
  <study_first_submitted_qc>August 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2013</study_first_posted>
  <results_first_submitted>June 18, 2020</results_first_submitted>
  <results_first_submitted_qc>June 18, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2020</results_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis of knee</keyword>
  <keyword>Recombinant Human Fibroblast Growth Factor-18 (rhFGF-18)</keyword>
  <keyword>Sprifermin</keyword>
  <keyword>Placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 5, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT01919164/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 11, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/64/NCT01919164/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 549 participants were randomized in this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received Placebo matched to Sprifermin as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
        </group>
        <group group_id="P2">
          <title>Sprifermin (AS902330) 30 mcg/Placebo - 2 Cycles</title>
          <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
        </group>
        <group group_id="P3">
          <title>Sprifermin (AS902330) 30 mcg- 4 Cycles</title>
          <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
        </group>
        <group group_id="P4">
          <title>Sprifermin (AS902330) 100 mcg/Placebo (2 Cycles)</title>
          <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
        </group>
        <group group_id="P5">
          <title>Sprifermin (AS902330) 100 mcg- 4 Cycles</title>
          <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="110"/>
                <participants group_id="P3" count="111"/>
                <participants group_id="P4" count="110"/>
                <participants group_id="P5" count="110"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="109">1 participant assigned to Placebo arm who inadvertently received 30 mcg was included in this arm.</participants>
                <participants group_id="P3" count="111"/>
                <participants group_id="P4" count="111">1 participant in Sprifermin2 Cycles arm who inadvertently received 100 mcg was included in this arm.</participants>
                <participants group_id="P5" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="65"/>
                <participants group_id="P2" count="80"/>
                <participants group_id="P3" count="74"/>
                <participants group_id="P4" count="82"/>
                <participants group_id="P5" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="33"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Un-specified</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received Placebo matched to Sprifermin as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
        </group>
        <group group_id="B2">
          <title>Sprifermin (AS902330) 30 mcg/Placebo - 2 Cycles</title>
          <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
        </group>
        <group group_id="B3">
          <title>Sprifermin (AS902330) 30 mcg- 4 Cycles</title>
          <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
        </group>
        <group group_id="B4">
          <title>Sprifermin (AS902330) 100 mcg/Placebo- 2 Cycles</title>
          <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
        </group>
        <group group_id="B5">
          <title>Sprifermin (AS902330) 100 mcg- 4 Cycles</title>
          <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="108"/>
            <count group_id="B2" value="110"/>
            <count group_id="B3" value="111"/>
            <count group_id="B4" value="110"/>
            <count group_id="B5" value="110"/>
            <count group_id="B6" value="549"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B5" value="46"/>
                    <measurement group_id="B6" value="250"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="59"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="64"/>
                    <measurement group_id="B6" value="299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="77"/>
                    <measurement group_id="B5" value="73"/>
                    <measurement group_id="B6" value="379"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="33"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="109"/>
                    <measurement group_id="B3" value="111"/>
                    <measurement group_id="B4" value="110"/>
                    <measurement group_id="B5" value="110"/>
                    <measurement group_id="B6" value="547"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="87"/>
                    <measurement group_id="B5" value="89"/>
                    <measurement group_id="B6" value="439"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Cartilage Thickness in the Total Femorotibial Joint as Evaluated by Quantitative Magnetic Resonance Imaging (qMRI) at Year 2</title>
        <description>The change in cartilage thickness at 2 years was calculated based on quantitative magnetic resonance imaging (qMRI).</description>
        <time_frame>Baseline, Year 2 (Week 104)</time_frame>
        <population>Modified intent to treat (ITT) analysis set included all randomized participants that is, only planned treatment regimen was used and who had a baseline, at least 1 post-treatment qMRI assessment available in double-blind placebo-controlled part. Here “Number of Participants analyzed” = participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received Placebo matched to Sprifermin as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Sprifermin (AS902330) 30 mcg/Placebo - 2 Cycles</title>
            <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Sprifermin (AS902330) 30 mcg- 4 Cycles</title>
            <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Sprifermin (AS902330) 100 mcg/Placebo (2 Cycles)</title>
            <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O5">
            <title>Sprifermin (AS902330) 100 mcg- 4 Cycles</title>
            <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cartilage Thickness in the Total Femorotibial Joint as Evaluated by Quantitative Magnetic Resonance Imaging (qMRI) at Year 2</title>
          <description>The change in cartilage thickness at 2 years was calculated based on quantitative magnetic resonance imaging (qMRI).</description>
          <population>Modified intent to treat (ITT) analysis set included all randomized participants that is, only planned treatment regimen was used and who had a baseline, at least 1 post-treatment qMRI assessment available in double-blind placebo-controlled part. Here “Number of Participants analyzed” = participants evaluable for this outcome measure.</population>
          <units>millimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="90"/>
                <count group_id="O5" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.07"/>
                    <measurement group_id="O2" value="-0.01" spread="0.07"/>
                    <measurement group_id="O3" value="0.00" spread="0.07"/>
                    <measurement group_id="O4" value="0.02" spread="0.08"/>
                    <measurement group_id="O5" value="0.03" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Descriptive statistics was provided for primary endpoint.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.01</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Descriptive statistics was provided for primary endpoint.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.01</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Descriptive statistics was provided for primary endpoint.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.02</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Descriptive statistics was provided for primary endpoint.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.03</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale, Stiffness Subscale, Physical Function Subscale and Total Score at Week 52, Week 78 and Week 104</title>
        <description>WOMAC pain subscale consists of 5 questions (Likert Scale) relating to pain. Sum of items of pain subscale ranges from 0-11. Higher scores=worse pain. Stiffness subscale consists of 2 questions relating articular function. Sum of items of stiffness subscale ranges from 0-8. Higher scores=worse function. Physical function subscale consists of 17 question relating to physical activities. Sum of items of physical function subscale ranges from 0-68. Higher scores= worse functional limitations. Each sub-scale is directly transformed into a 0-100 scale, where higher score indicates worse condition. WOMAC total score(24questions) is sum of total subscales which was directly transformed into score range from 0-100. Higher scores=worse condition. Negative value in change is indicative of improvement.</description>
        <time_frame>Baseline, Week 52, Week 78 and Week 104</time_frame>
        <population>Intention-to-Treat (ITT) analysis set included all participants randomly allocated to a treatment, based on the intention to treat “as randomized” principle. Here “Number of Participants analyzed” = participants evaluable for this outcome measure and &quot;Number analyzed&quot; included those who were evaluable at specified timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received Placebo matched to Sprifermin as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Sprifermin (AS902330) 30 mcg/Placebo - 2 Cycles</title>
            <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Sprifermin (AS902330) 30 mcg- 4 Cycles</title>
            <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Sprifermin (AS902330) 100 mcg/Placebo (2 Cycles)</title>
            <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O5">
            <title>Sprifermin (AS902330) 100 mcg- 4 Cycles</title>
            <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale, Stiffness Subscale, Physical Function Subscale and Total Score at Week 52, Week 78 and Week 104</title>
          <description>WOMAC pain subscale consists of 5 questions (Likert Scale) relating to pain. Sum of items of pain subscale ranges from 0-11. Higher scores=worse pain. Stiffness subscale consists of 2 questions relating articular function. Sum of items of stiffness subscale ranges from 0-8. Higher scores=worse function. Physical function subscale consists of 17 question relating to physical activities. Sum of items of physical function subscale ranges from 0-68. Higher scores= worse functional limitations. Each sub-scale is directly transformed into a 0-100 scale, where higher score indicates worse condition. WOMAC total score(24questions) is sum of total subscales which was directly transformed into score range from 0-100. Higher scores=worse condition. Negative value in change is indicative of improvement.</description>
          <population>Intention-to-Treat (ITT) analysis set included all participants randomly allocated to a treatment, based on the intention to treat “as randomized” principle. Here “Number of Participants analyzed” = participants evaluable for this outcome measure and &quot;Number analyzed&quot; included those who were evaluable at specified timepoints.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="98"/>
                <count group_id="O3" value="89"/>
                <count group_id="O4" value="98"/>
                <count group_id="O5" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain: Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="98"/>
                    <count group_id="O5" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.51" spread="19.49"/>
                    <measurement group_id="O2" value="-21.55" spread="18.36"/>
                    <measurement group_id="O3" value="-15.40" spread="18.31"/>
                    <measurement group_id="O4" value="-21.12" spread="19.73"/>
                    <measurement group_id="O5" value="-23.34" spread="17.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Change at Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="86"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.04" spread="20.81"/>
                    <measurement group_id="O2" value="-23.00" spread="20.42"/>
                    <measurement group_id="O3" value="-18.19" spread="21.15"/>
                    <measurement group_id="O4" value="-23.21" spread="19.42"/>
                    <measurement group_id="O5" value="-23.23" spread="18.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain: Change at Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="89"/>
                    <count group_id="O4" value="96"/>
                    <count group_id="O5" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.37" spread="20.60"/>
                    <measurement group_id="O2" value="-23.22" spread="21.42"/>
                    <measurement group_id="O3" value="-21.42" spread="21.37"/>
                    <measurement group_id="O4" value="-23.15" spread="18.18"/>
                    <measurement group_id="O5" value="-26.06" spread="18.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stiffness: Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="98"/>
                    <count group_id="O5" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.88" spread="24.72"/>
                    <measurement group_id="O2" value="-18.52" spread="22.89"/>
                    <measurement group_id="O3" value="-11.09" spread="21.14"/>
                    <measurement group_id="O4" value="-16.68" spread="20.93"/>
                    <measurement group_id="O5" value="-17.35" spread="22.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stiffness: Change at Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="86"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.44" spread="26.76"/>
                    <measurement group_id="O2" value="-19.47" spread="25.87"/>
                    <measurement group_id="O3" value="-14.94" spread="23.66"/>
                    <measurement group_id="O4" value="-19.63" spread="20.38"/>
                    <measurement group_id="O5" value="-21.44" spread="23.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stiffness: Change at Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="89"/>
                    <count group_id="O4" value="96"/>
                    <count group_id="O5" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.20" spread="25.84"/>
                    <measurement group_id="O2" value="-20.56" spread="23.93"/>
                    <measurement group_id="O3" value="-17.75" spread="22.74"/>
                    <measurement group_id="O4" value="-17.76" spread="20.75"/>
                    <measurement group_id="O5" value="-22.79" spread="24.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Function: Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="98"/>
                    <count group_id="O5" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.51" spread="19.14"/>
                    <measurement group_id="O2" value="-16.84" spread="17.64"/>
                    <measurement group_id="O3" value="-12.01" spread="18.04"/>
                    <measurement group_id="O4" value="-14.80" spread="19.07"/>
                    <measurement group_id="O5" value="-16.91" spread="19.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Function: Change at Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="86"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.38" spread="21.01"/>
                    <measurement group_id="O2" value="-18.23" spread="19.41"/>
                    <measurement group_id="O3" value="-16.00" spread="20.82"/>
                    <measurement group_id="O4" value="-17.51" spread="18.96"/>
                    <measurement group_id="O5" value="-19.29" spread="19.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Function: Change at Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="89"/>
                    <count group_id="O4" value="98"/>
                    <count group_id="O5" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.89" spread="20.10"/>
                    <measurement group_id="O2" value="-20.00" spread="20.99"/>
                    <measurement group_id="O3" value="-19.06" spread="21.52"/>
                    <measurement group_id="O4" value="-17.03" spread="20.16"/>
                    <measurement group_id="O5" value="-20.82" spread="20.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total: Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="98"/>
                    <count group_id="O5" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.42" spread="18.61"/>
                    <measurement group_id="O2" value="-17.97" spread="16.95"/>
                    <measurement group_id="O3" value="-12.64" spread="17.42"/>
                    <measurement group_id="O4" value="-16.29" spread="18.35"/>
                    <measurement group_id="O5" value="-18.29" spread="18.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total: Change at Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="94"/>
                    <count group_id="O3" value="86"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.41" spread="20.43"/>
                    <measurement group_id="O2" value="-19.34" spread="19.15"/>
                    <measurement group_id="O3" value="-16.36" spread="20.35"/>
                    <measurement group_id="O4" value="-18.88" spread="18.15"/>
                    <measurement group_id="O5" value="-20.29" spread="18.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total: Change at Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="86"/>
                    <count group_id="O2" value="98"/>
                    <count group_id="O3" value="89"/>
                    <count group_id="O4" value="96"/>
                    <count group_id="O5" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.02" spread="19.70"/>
                    <measurement group_id="O2" value="-20.73" spread="20.22"/>
                    <measurement group_id="O3" value="-19.44" spread="20.88"/>
                    <measurement group_id="O4" value="-18.37" spread="18.69"/>
                    <measurement group_id="O5" value="-22.08" spread="19.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the 20-meter Walk Test at Week 12, 26, 38, 52, 64, 78, 90 and 104</title>
        <description>The 20-meter walk test is an objective test of physical function which consists of measuring the time needed for the participant to walk 20 meters at a normal pace. A stopwatch was used for time measurement.</description>
        <time_frame>Baseline, Week 12, 26, 38, 52, 64, 78, 90 and 104</time_frame>
        <population>Intention-to-Treat (ITT) analysis set included all participants randomly allocated to a treatment, based on the intention to treat “as randomized” principle. Here “Number of Participants analyzed” = participants evaluable for this outcome measure and &quot;Number analyzed&quot; included those who were evaluable at specified timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received Placebo matched to Sprifermin as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Sprifermin (AS902330) 30 mcg/Placebo - 2 Cycles</title>
            <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Sprifermin (AS902330) 30 mcg- 4 Cycles</title>
            <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Sprifermin (AS902330) 100 mcg/Placebo (2 Cycles)</title>
            <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O5">
            <title>Sprifermin (AS902330) 100 mcg- 4 Cycles</title>
            <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the 20-meter Walk Test at Week 12, 26, 38, 52, 64, 78, 90 and 104</title>
          <description>The 20-meter walk test is an objective test of physical function which consists of measuring the time needed for the participant to walk 20 meters at a normal pace. A stopwatch was used for time measurement.</description>
          <population>Intention-to-Treat (ITT) analysis set included all participants randomly allocated to a treatment, based on the intention to treat “as randomized” principle. Here “Number of Participants analyzed” = participants evaluable for this outcome measure and &quot;Number analyzed&quot; included those who were evaluable at specified timepoints.</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="107"/>
                <count group_id="O5" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="105"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="109"/>
                    <count group_id="O4" value="107"/>
                    <count group_id="O5" value="108"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2" spread="2.9"/>
                    <measurement group_id="O2" value="-0.4" spread="4.0"/>
                    <measurement group_id="O3" value="-0.5" spread="2.6"/>
                    <measurement group_id="O4" value="-0.8" spread="2.2"/>
                    <measurement group_id="O5" value="-1.1" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="99"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="101"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="3.7"/>
                    <measurement group_id="O2" value="-0.4" spread="3.9"/>
                    <measurement group_id="O3" value="-0.3" spread="2.6"/>
                    <measurement group_id="O4" value="-1.1" spread="2.8"/>
                    <measurement group_id="O5" value="-1.3" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 38</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="98"/>
                    <count group_id="O4" value="102"/>
                    <count group_id="O5" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="3.6"/>
                    <measurement group_id="O2" value="-0.5" spread="3.4"/>
                    <measurement group_id="O3" value="-0.7" spread="2.5"/>
                    <measurement group_id="O4" value="-1.0" spread="2.9"/>
                    <measurement group_id="O5" value="-1.4" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="90"/>
                    <count group_id="O4" value="101"/>
                    <count group_id="O5" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="4.2"/>
                    <measurement group_id="O2" value="-1.1" spread="3.6"/>
                    <measurement group_id="O3" value="-0.7" spread="2.5"/>
                    <measurement group_id="O4" value="-0.4" spread="7.9"/>
                    <measurement group_id="O5" value="-1.3" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="93"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="3.6"/>
                    <measurement group_id="O2" value="-1.5" spread="4.1"/>
                    <measurement group_id="O3" value="-0.9" spread="2.5"/>
                    <measurement group_id="O4" value="-1.3" spread="2.6"/>
                    <measurement group_id="O5" value="-1.6" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="88"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="3.7"/>
                    <measurement group_id="O2" value="-1.0" spread="4.0"/>
                    <measurement group_id="O3" value="-0.8" spread="2.8"/>
                    <measurement group_id="O4" value="-1.6" spread="3.0"/>
                    <measurement group_id="O5" value="-1.3" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="91"/>
                    <count group_id="O5" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="3.9"/>
                    <measurement group_id="O2" value="-1.0" spread="3.2"/>
                    <measurement group_id="O3" value="-1.1" spread="2.7"/>
                    <measurement group_id="O4" value="-1.8" spread="3.1"/>
                    <measurement group_id="O5" value="-1.7" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="91"/>
                    <count group_id="O4" value="99"/>
                    <count group_id="O5" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="4.0"/>
                    <measurement group_id="O2" value="-1.2" spread="4.1"/>
                    <measurement group_id="O3" value="-0.8" spread="3.4"/>
                    <measurement group_id="O4" value="-1.4" spread="2.9"/>
                    <measurement group_id="O5" value="-1.3" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Patient's Global Assessment (PGA) at Week 12, 26, 38, 52, 64, 78, 90 and 104</title>
        <description>The Patient Global Assessment is based on participant's answer to the question &quot;Considering all the ways your osteoarthritis of the knee has affected you during the last 48 Hours, select the number that best describes the impact of your knee osteoarthritis on your daily life&quot;, and can take on values between 0-10 (0=None, 10=Extreme), for summaries the values are rescaled to 0-100 by multiplication with 10. Higher scores indicated worsening of condition. A negative value in change in Patient's Global Assessment is indicative of an improvement.</description>
        <time_frame>Baseline, Week 12, 26, 38, 52, 64, 78, 90 and 104</time_frame>
        <population>Intention-to-Treat (ITT) analysis set included all participants randomly allocated to a treatment, based on the intention to treat “as randomized” principle. Here “Number of Participants analyzed” = participants evaluable for this outcome measure and &quot;Number analyzed&quot; included those who were evaluable at specified timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received Placebo matched to Sprifermin as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Sprifermin (AS902330) 30 mcg/Placebo - 2 Cycles</title>
            <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Sprifermin (AS902330) 30 mcg- 4 Cycles</title>
            <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Sprifermin (AS902330) 100 mcg/Placebo (2 Cycles)</title>
            <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O5">
            <title>Sprifermin (AS902330) 100 mcg- 4 Cycles</title>
            <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Patient's Global Assessment (PGA) at Week 12, 26, 38, 52, 64, 78, 90 and 104</title>
          <description>The Patient Global Assessment is based on participant's answer to the question &quot;Considering all the ways your osteoarthritis of the knee has affected you during the last 48 Hours, select the number that best describes the impact of your knee osteoarthritis on your daily life&quot;, and can take on values between 0-10 (0=None, 10=Extreme), for summaries the values are rescaled to 0-100 by multiplication with 10. Higher scores indicated worsening of condition. A negative value in change in Patient's Global Assessment is indicative of an improvement.</description>
          <population>Intention-to-Treat (ITT) analysis set included all participants randomly allocated to a treatment, based on the intention to treat “as randomized” principle. Here “Number of Participants analyzed” = participants evaluable for this outcome measure and &quot;Number analyzed&quot; included those who were evaluable at specified timepoints.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="108"/>
                <count group_id="O3" value="109"/>
                <count group_id="O4" value="106"/>
                <count group_id="O5" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="104"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="109"/>
                    <count group_id="O4" value="106"/>
                    <count group_id="O5" value="107"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.6" spread="23.5"/>
                    <measurement group_id="O2" value="-13.9" spread="20.6"/>
                    <measurement group_id="O3" value="-17.0" spread="25.0"/>
                    <measurement group_id="O4" value="-15.0" spread="23.2"/>
                    <measurement group_id="O5" value="-16.7" spread="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="99"/>
                    <count group_id="O2" value="108"/>
                    <count group_id="O3" value="100"/>
                    <count group_id="O4" value="103"/>
                    <count group_id="O5" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.3" spread="22.3"/>
                    <measurement group_id="O2" value="-15.1" spread="22.7"/>
                    <measurement group_id="O3" value="-17.7" spread="25.3"/>
                    <measurement group_id="O4" value="-18.7" spread="22.4"/>
                    <measurement group_id="O5" value="-19.1" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 38</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="98"/>
                    <count group_id="O2" value="103"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="102"/>
                    <count group_id="O5" value="98"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.9" spread="26.2"/>
                    <measurement group_id="O2" value="-17.2" spread="22.5"/>
                    <measurement group_id="O3" value="-19.2" spread="24.9"/>
                    <measurement group_id="O4" value="-20.5" spread="24.3"/>
                    <measurement group_id="O5" value="-18.4" spread="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="88"/>
                    <count group_id="O4" value="101"/>
                    <count group_id="O5" value="100"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.6" spread="25.8"/>
                    <measurement group_id="O2" value="-20.9" spread="21.2"/>
                    <measurement group_id="O3" value="-18.0" spread="23.9"/>
                    <measurement group_id="O4" value="-19.5" spread="25.2"/>
                    <measurement group_id="O5" value="-21.6" spread="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="93"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.7" spread="24.6"/>
                    <measurement group_id="O2" value="-21.7" spread="21.9"/>
                    <measurement group_id="O3" value="-22.3" spread="23.0"/>
                    <measurement group_id="O4" value="-21.6" spread="25.8"/>
                    <measurement group_id="O5" value="-21.3" spread="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="96"/>
                    <count group_id="O3" value="88"/>
                    <count group_id="O4" value="97"/>
                    <count group_id="O5" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.7" spread="26.5"/>
                    <measurement group_id="O2" value="-21.5" spread="24.1"/>
                    <measurement group_id="O3" value="-23.1" spread="25.7"/>
                    <measurement group_id="O4" value="-22.0" spread="25.4"/>
                    <measurement group_id="O5" value="-24.2" spread="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="87"/>
                    <count group_id="O4" value="91"/>
                    <count group_id="O5" value="87"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.8" spread="25.6"/>
                    <measurement group_id="O2" value="-22.3" spread="24.5"/>
                    <measurement group_id="O3" value="-21.7" spread="24.8"/>
                    <measurement group_id="O4" value="-21.1" spread="26.3"/>
                    <measurement group_id="O5" value="-26.2" spread="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="87"/>
                    <count group_id="O2" value="100"/>
                    <count group_id="O3" value="91"/>
                    <count group_id="O4" value="99"/>
                    <count group_id="O5" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.5" spread="25.0"/>
                    <measurement group_id="O2" value="-23.0" spread="22.3"/>
                    <measurement group_id="O3" value="-23.8" spread="24.9"/>
                    <measurement group_id="O4" value="-22.1" spread="25.6"/>
                    <measurement group_id="O5" value="-25.8" spread="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Minimal Joint Space Width (mJSW) in the Medial and Lateral Compartments as Evaluated by X-ray at Week 52 and 104</title>
        <description>Change in joint space narrowing was visualized with the &quot;fixed flexion&quot; knee radiograph. Determination of joint space narrowing by X-ray is considered to be a semi-quantitative method for assessment of progression of knee Osteoarthritis (OA). X-rays of both the target knee and the contralateral knee were performed. X-rays were read centrally. X-ray images were used to measure mJSW in the medial femorotibial and lateral femorotibial compartments and to determine the participant's baseline Kellgren-Lawrence grades (KLG).</description>
        <time_frame>Baseline, Week 52 and 104</time_frame>
        <population>Intention-to-Treat (ITT) analysis set included all participants randomly allocated to a treatment, based on the intention to treat “as randomized” principle. Here “Number of Participants analyzed” = participants evaluable for this outcome measure and &quot;Number analyzed&quot; included those who were evaluable at specified timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received Placebo matched to Sprifermin as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Sprifermin (AS902330) 30 mcg/Placebo - 2 Cycles</title>
            <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Sprifermin (AS902330) 30 mcg- 4 Cycles</title>
            <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Sprifermin (AS902330) 100 mcg/Placebo (2 Cycles)</title>
            <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O5">
            <title>Sprifermin (AS902330) 100 mcg- 4 Cycles</title>
            <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Minimal Joint Space Width (mJSW) in the Medial and Lateral Compartments as Evaluated by X-ray at Week 52 and 104</title>
          <description>Change in joint space narrowing was visualized with the &quot;fixed flexion&quot; knee radiograph. Determination of joint space narrowing by X-ray is considered to be a semi-quantitative method for assessment of progression of knee Osteoarthritis (OA). X-rays of both the target knee and the contralateral knee were performed. X-rays were read centrally. X-ray images were used to measure mJSW in the medial femorotibial and lateral femorotibial compartments and to determine the participant's baseline Kellgren-Lawrence grades (KLG).</description>
          <population>Intention-to-Treat (ITT) analysis set included all participants randomly allocated to a treatment, based on the intention to treat “as randomized” principle. Here “Number of Participants analyzed” = participants evaluable for this outcome measure and &quot;Number analyzed&quot; included those who were evaluable at specified timepoints.</population>
          <units>millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Medial: Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="89"/>
                    <count group_id="O4" value="100"/>
                    <count group_id="O5" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.48"/>
                    <measurement group_id="O2" value="-0.05" spread="0.53"/>
                    <measurement group_id="O3" value="-0.04" spread="0.43"/>
                    <measurement group_id="O4" value="0.02" spread="0.55"/>
                    <measurement group_id="O5" value="-0.04" spread="0.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medial: Change at Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="95"/>
                    <count group_id="O4" value="98"/>
                    <count group_id="O5" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.59"/>
                    <measurement group_id="O2" value="-0.09" spread="0.73"/>
                    <measurement group_id="O3" value="0.03" spread="0.52"/>
                    <measurement group_id="O4" value="-0.05" spread="0.66"/>
                    <measurement group_id="O5" value="-0.07" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lateral: Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="95"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="89"/>
                    <count group_id="O4" value="100"/>
                    <count group_id="O5" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.46"/>
                    <measurement group_id="O2" value="-0.03" spread="0.62"/>
                    <measurement group_id="O3" value="0.16" spread="0.54"/>
                    <measurement group_id="O4" value="0.10" spread="0.37"/>
                    <measurement group_id="O5" value="0.14" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lateral: Change at Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="90"/>
                    <count group_id="O2" value="101"/>
                    <count group_id="O3" value="95"/>
                    <count group_id="O4" value="98"/>
                    <count group_id="O5" value="95"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.49"/>
                    <measurement group_id="O2" value="-0.03" spread="0.64"/>
                    <measurement group_id="O3" value="0.01" spread="0.65"/>
                    <measurement group_id="O4" value="0.19" spread="0.49"/>
                    <measurement group_id="O5" value="0.19" spread="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cartilage Thickness in the Medial and Lateral Compartments as Well as in the Total Femorotibial Joint</title>
        <description>The change in cartilage thickness was calculated based on quantitative magnetic resonance imaging (qMRI).</description>
        <time_frame>Medial and Lateral: Baseline, Week 26, 52, 78 and 104; Total: Baseline, Week 26, 52 and 78</time_frame>
        <population>Modified ITT analysis set was used. Here “Number of Participants analyzed” = participants evaluable for this outcome measure and &quot;Number analyzed&quot; included those who were evaluable at specified timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received Placebo matched to Sprifermin as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Sprifermin (AS902330) 30 mcg/Placebo - 2 Cycles</title>
            <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Sprifermin (AS902330) 30 mcg- 4 Cycles</title>
            <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Sprifermin (AS902330) 100 mcg/Placebo (2 Cycles)</title>
            <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O5">
            <title>Sprifermin (AS902330) 100 mcg- 4 Cycles</title>
            <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cartilage Thickness in the Medial and Lateral Compartments as Well as in the Total Femorotibial Joint</title>
          <description>The change in cartilage thickness was calculated based on quantitative magnetic resonance imaging (qMRI).</description>
          <population>Modified ITT analysis set was used. Here “Number of Participants analyzed” = participants evaluable for this outcome measure and &quot;Number analyzed&quot; included those who were evaluable at specified timepoints.</population>
          <units>millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="97"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Medial: Change at Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="95"/>
                    <count group_id="O4" value="95"/>
                    <count group_id="O5" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.06"/>
                    <measurement group_id="O2" value="0.00" spread="0.06"/>
                    <measurement group_id="O3" value="-0.01" spread="0.06"/>
                    <measurement group_id="O4" value="0.01" spread="0.05"/>
                    <measurement group_id="O5" value="0.01" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medial: Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.06"/>
                    <measurement group_id="O2" value="-0.01" spread="0.07"/>
                    <measurement group_id="O3" value="-0.01" spread="0.06"/>
                    <measurement group_id="O4" value="0.00" spread="0.07"/>
                    <measurement group_id="O5" value="0.01" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medial: Change at Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.07"/>
                    <measurement group_id="O2" value="-0.01" spread="0.07"/>
                    <measurement group_id="O3" value="0.01" spread="0.06"/>
                    <measurement group_id="O4" value="0.01" spread="0.10"/>
                    <measurement group_id="O5" value="0.03" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medial: Change at Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.03" spread="0.12"/>
                    <measurement group_id="O2" value="-0.02" spread="0.10"/>
                    <measurement group_id="O3" value="-0.01" spread="0.08"/>
                    <measurement group_id="O4" value="0.00" spread="0.11"/>
                    <measurement group_id="O5" value="0.02" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lateral: Change at Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="96"/>
                    <count group_id="O5" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.05"/>
                    <measurement group_id="O2" value="0.00" spread="0.05"/>
                    <measurement group_id="O3" value="0.00" spread="0.06"/>
                    <measurement group_id="O4" value="0.02" spread="0.05"/>
                    <measurement group_id="O5" value="0.02" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lateral: Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="95"/>
                    <count group_id="O5" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.05"/>
                    <measurement group_id="O2" value="-0.01" spread="0.07"/>
                    <measurement group_id="O3" value="0.00" spread="0.05"/>
                    <measurement group_id="O4" value="0.02" spread="0.06"/>
                    <measurement group_id="O5" value="0.02" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lateral: Change at Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="91"/>
                    <count group_id="O5" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.05"/>
                    <measurement group_id="O2" value="0.01" spread="0.06"/>
                    <measurement group_id="O3" value="0.01" spread="0.08"/>
                    <measurement group_id="O4" value="0.03" spread="0.07"/>
                    <measurement group_id="O5" value="0.03" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lateral: Change at Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="91"/>
                    <count group_id="O5" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.05"/>
                    <measurement group_id="O2" value="-0.01" spread="0.07"/>
                    <measurement group_id="O3" value="0.00" spread="0.09"/>
                    <measurement group_id="O4" value="0.04" spread="0.07"/>
                    <measurement group_id="O5" value="0.04" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total: Change at Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="95"/>
                    <count group_id="O4" value="95"/>
                    <count group_id="O5" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.05"/>
                    <measurement group_id="O2" value="0.00" spread="0.04"/>
                    <measurement group_id="O3" value="0.00" spread="0.05"/>
                    <measurement group_id="O4" value="0.01" spread="0.04"/>
                    <measurement group_id="O5" value="0.01" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total: Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.05"/>
                    <measurement group_id="O2" value="-0.01" spread="0.06"/>
                    <measurement group_id="O3" value="0.00" spread="0.05"/>
                    <measurement group_id="O4" value="0.01" spread="0.06"/>
                    <measurement group_id="O5" value="0.01" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total: Change at Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.05"/>
                    <measurement group_id="O2" value="0.00" spread="0.06"/>
                    <measurement group_id="O3" value="0.06" spread="0.06"/>
                    <measurement group_id="O4" value="0.02" spread="0.07"/>
                    <measurement group_id="O5" value="0.03" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cartilage-Volume in the Medial and Lateral Compartments as Well as in the Total Femorotibial Joint at Week 26, 52, 78 and 104</title>
        <description>The change in cartilage volume in the medial and lateral compartments as well as in the total femorotibial joint at Week 26, 52, 78 and 104 was calculated based on qMRI.</description>
        <time_frame>Baseline, Week 26, 52, 78 and 104</time_frame>
        <population>Modified ITT analysis set was used. Here “Number of Participants analyzed” = participants evaluable for this outcome measure and &quot;Number analyzed&quot; included those who were evaluable at specified timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received Placebo matched to Sprifermin as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Sprifermin (AS902330) 30 mcg/Placebo - 2 Cycles</title>
            <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Sprifermin (AS902330) 30 mcg- 4 Cycles</title>
            <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Sprifermin (AS902330) 100 mcg/Placebo (2 Cycles)</title>
            <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O5">
            <title>Sprifermin (AS902330) 100 mcg- 4 Cycles</title>
            <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cartilage-Volume in the Medial and Lateral Compartments as Well as in the Total Femorotibial Joint at Week 26, 52, 78 and 104</title>
          <description>The change in cartilage volume in the medial and lateral compartments as well as in the total femorotibial joint at Week 26, 52, 78 and 104 was calculated based on qMRI.</description>
          <population>Modified ITT analysis set was used. Here “Number of Participants analyzed” = participants evaluable for this outcome measure and &quot;Number analyzed&quot; included those who were evaluable at specified timepoints.</population>
          <units>microliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="94"/>
                <count group_id="O2" value="97"/>
                <count group_id="O3" value="97"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Medial: Change at Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="95"/>
                    <count group_id="O4" value="95"/>
                    <count group_id="O5" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="112.2"/>
                    <measurement group_id="O2" value="1.7" spread="110.8"/>
                    <measurement group_id="O3" value="-3.2" spread="99.5"/>
                    <measurement group_id="O4" value="16.7" spread="89.8"/>
                    <measurement group_id="O5" value="16.5" spread="114.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medial: Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.2" spread="100.7"/>
                    <measurement group_id="O2" value="-2.9" spread="127.1"/>
                    <measurement group_id="O3" value="-7.0" spread="103.7"/>
                    <measurement group_id="O4" value="3.6" spread="127.5"/>
                    <measurement group_id="O5" value="16.5" spread="110.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medial: Change at Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.9" spread="125.3"/>
                    <measurement group_id="O2" value="-7.0" spread="153.7"/>
                    <measurement group_id="O3" value="23.6" spread="109.3"/>
                    <measurement group_id="O4" value="33.2" spread="177.0"/>
                    <measurement group_id="O5" value="53.9" spread="147.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Medial: Change at Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-41.0" spread="192.1"/>
                    <measurement group_id="O2" value="-21.4" spread="198.3"/>
                    <measurement group_id="O3" value="3.6" spread="123.9"/>
                    <measurement group_id="O4" value="19.5" spread="202.3"/>
                    <measurement group_id="O5" value="48.6" spread="150.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lateral: Change at Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="97"/>
                    <count group_id="O4" value="96"/>
                    <count group_id="O5" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.8" spread="84.4"/>
                    <measurement group_id="O2" value="0.8" spread="82.0"/>
                    <measurement group_id="O3" value="1.5" spread="102.3"/>
                    <measurement group_id="O4" value="31.3" spread="87.7"/>
                    <measurement group_id="O5" value="25.1" spread="85.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lateral: Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="95"/>
                    <count group_id="O5" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.7" spread="94.0"/>
                    <measurement group_id="O2" value="-17.5" spread="141.1"/>
                    <measurement group_id="O3" value="2.7" spread="98.2"/>
                    <measurement group_id="O4" value="32.4" spread="107.5"/>
                    <measurement group_id="O5" value="28.1" spread="87.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lateral: Change at Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="85"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="91"/>
                    <count group_id="O5" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="89.7"/>
                    <measurement group_id="O2" value="13.9" spread="113.6"/>
                    <measurement group_id="O3" value="21.6" spread="129.0"/>
                    <measurement group_id="O4" value="55.9" spread="123.1"/>
                    <measurement group_id="O5" value="55.2" spread="101.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lateral: Change at Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="85"/>
                    <count group_id="O4" value="91"/>
                    <count group_id="O5" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.5" spread="87.2"/>
                    <measurement group_id="O2" value="-6.8" spread="144.9"/>
                    <measurement group_id="O3" value="7.2" spread="134.8"/>
                    <measurement group_id="O4" value="75.5" spread="111.8"/>
                    <measurement group_id="O5" value="67.9" spread="112.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total: Change at Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="93"/>
                    <count group_id="O2" value="97"/>
                    <count group_id="O3" value="95"/>
                    <count group_id="O4" value="95"/>
                    <count group_id="O5" value="99"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.0" spread="163.2"/>
                    <measurement group_id="O2" value="2.5" spread="147.0"/>
                    <measurement group_id="O3" value="-2.9" spread="161.8"/>
                    <measurement group_id="O4" value="48.4" spread="150.9"/>
                    <measurement group_id="O5" value="41.5" spread="166.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total: Change at Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                    <count group_id="O2" value="93"/>
                    <count group_id="O3" value="81"/>
                    <count group_id="O4" value="94"/>
                    <count group_id="O5" value="93"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.7" spread="155.7"/>
                    <measurement group_id="O2" value="-20.4" spread="217.6"/>
                    <measurement group_id="O3" value="-5.5" spread="169.0"/>
                    <measurement group_id="O4" value="36.2" spread="203.1"/>
                    <measurement group_id="O5" value="44.7" spread="163.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total: Change at Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="84"/>
                    <count group_id="O2" value="91"/>
                    <count group_id="O3" value="84"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="89"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.3" spread="176.8"/>
                    <measurement group_id="O2" value="6.9" spread="228.1"/>
                    <measurement group_id="O3" value="44.8" spread="195.3"/>
                    <measurement group_id="O4" value="89.9" spread="272.6"/>
                    <measurement group_id="O5" value="109.1" spread="219.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total: Change at Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="83"/>
                    <count group_id="O2" value="92"/>
                    <count group_id="O3" value="83"/>
                    <count group_id="O4" value="90"/>
                    <count group_id="O5" value="86"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-55.5" spread="239.5"/>
                    <measurement group_id="O2" value="-28.2" spread="275.7"/>
                    <measurement group_id="O3" value="9.5" spread="205.7"/>
                    <measurement group_id="O4" value="96.6" spread="271.1"/>
                    <measurement group_id="O5" value="116.5" spread="233.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Synovial Fluid Levels of Sprifermin/FGF-18</title>
        <description>Levels of sprifermin/FGF-18 in synovial fluid were measured to provide a first estimate of the residence time of sprifermin in the synovial fluid.</description>
        <time_frame>Pre-dose at Week 0, 2 hours post-dose at Week 1 and 2 of Cycle 1, 2, 3 and 4 (each cycle is of 28 days)</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of study treatment. Arm assignments for participants in Safety Set were based on actual treatment received. Here “Number of Participants analyzed” = participants evaluable for this outcome measure and &quot;Number analyzed&quot; are those who were evaluable at specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received Placebo matched to Sprifermin as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Sprifermin (AS902330) 30 mcg/Placebo - 2 Cycles</title>
            <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Sprifermin (AS902330) 30 mcg- 4 Cycles</title>
            <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Sprifermin (AS902330) 100 mcg/Placebo (2 Cycles)</title>
            <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O5">
            <title>Sprifermin (AS902330) 100 mcg- 4 Cycles</title>
            <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Synovial Fluid Levels of Sprifermin/FGF-18</title>
          <description>Levels of sprifermin/FGF-18 in synovial fluid were measured to provide a first estimate of the residence time of sprifermin in the synovial fluid.</description>
          <population>Safety analysis set included all participants who received at least 1 dose of study treatment. Arm assignments for participants in Safety Set were based on actual treatment received. Here “Number of Participants analyzed” = participants evaluable for this outcome measure and &quot;Number analyzed&quot; are those who were evaluable at specified timepoint.</population>
          <units>picogram/milliliter</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="22"/>
                <count group_id="O4" value="25"/>
                <count group_id="O5" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 0; Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="56876.4" lower_limit="5843.8" upper_limit="86068.0"/>
                    <measurement group_id="O3" value="1006.5" lower_limit="206.6" upper_limit="34439.4"/>
                    <measurement group_id="O4" value="1386.1" lower_limit="260.4" upper_limit="36766.4"/>
                    <measurement group_id="O5" value="5896.4" lower_limit="631.3" upper_limit="238780.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1; Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="622.1" lower_limit="156.0" upper_limit="1088.2"/>
                    <measurement group_id="O2" value="3628.3" lower_limit="229.9" upper_limit="37140.5"/>
                    <measurement group_id="O3" value="1493.2" lower_limit="214.2" upper_limit="110515.4"/>
                    <measurement group_id="O4" value="359.8" lower_limit="151.2" upper_limit="37014.8"/>
                    <measurement group_id="O5" value="1062.3" lower_limit="156.7" upper_limit="840122.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2; Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="3150.9" lower_limit="189.1" upper_limit="33378.5"/>
                    <measurement group_id="O3" value="4167.0" lower_limit="460.3" upper_limit="8857.1"/>
                    <measurement group_id="O4" value="467.9" lower_limit="150.7" upper_limit="108866.0"/>
                    <measurement group_id="O5" value="258.2" lower_limit="171.9" upper_limit="48066.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0; Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202.5" lower_limit="202.5" upper_limit="202.5"/>
                    <measurement group_id="O3" value="7039.1" lower_limit="309.8" upper_limit="1108182.4"/>
                    <measurement group_id="O4" value="308.2" lower_limit="308.2" upper_limit="308.2"/>
                    <measurement group_id="O5" value="32360.2" lower_limit="559.9" upper_limit="683691.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1; Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="14756.3" lower_limit="904.6" upper_limit="359059.2"/>
                    <measurement group_id="O5" value="7036.9" lower_limit="159.9" upper_limit="82301.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2; Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="6408.3" lower_limit="154.4" upper_limit="220629.5"/>
                    <measurement group_id="O5" value="1146.7" lower_limit="156.1" upper_limit="42598.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0; Cycle 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="20"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="463.7" lower_limit="223.8" upper_limit="5386.5"/>
                    <measurement group_id="O2" value="8019.3" lower_limit="279.2" upper_limit="358231.4"/>
                    <measurement group_id="O3" value="9443.4" lower_limit="505.7" upper_limit="271320.6"/>
                    <measurement group_id="O4" value="16901.2" lower_limit="461.0" upper_limit="273247.0"/>
                    <measurement group_id="O5" value="20753.0" lower_limit="4119.1" upper_limit="303440.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1; Cycle 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="8607.6" lower_limit="276.7" upper_limit="147723.9"/>
                    <measurement group_id="O3" value="4605.1" lower_limit="337.2" upper_limit="358029.6"/>
                    <measurement group_id="O4" value="3908.8" lower_limit="177.5" upper_limit="86823.9"/>
                    <measurement group_id="O5" value="10160.0" lower_limit="165.5" upper_limit="375638.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2; Cycle 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="25"/>
                    <count group_id="O5" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="260.9" lower_limit="260.9" upper_limit="260.9"/>
                    <measurement group_id="O2" value="9592.2" lower_limit="1277.1" upper_limit="35615.5"/>
                    <measurement group_id="O3" value="9422.2" lower_limit="409.3" upper_limit="353582.4"/>
                    <measurement group_id="O4" value="1801.0" lower_limit="171.9" upper_limit="77338.9"/>
                    <measurement group_id="O5" value="4161.7" lower_limit="151.1" upper_limit="213692.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 0; Cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="12458.4" lower_limit="224.6" upper_limit="163129.3"/>
                    <measurement group_id="O5" value="22132.1" lower_limit="215.7" upper_limit="897758.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1; Cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="215.3" lower_limit="215.3" upper_limit="215.3"/>
                    <measurement group_id="O3" value="9602.7" lower_limit="178.6" upper_limit="45631.9"/>
                    <measurement group_id="O4" value="2285.2" lower_limit="2285.2" upper_limit="2285.2"/>
                    <measurement group_id="O5" value="11468.3" lower_limit="157.5" upper_limit="142318.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2; Cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10670.0" lower_limit="10670.0" upper_limit="10670.0"/>
                    <measurement group_id="O3" value="7103.8" lower_limit="196.8" upper_limit="384511.5"/>
                    <measurement group_id="O4" value="331.1" lower_limit="168.4" upper_limit="493.7"/>
                    <measurement group_id="O5" value="8026.4" lower_limit="179.7" upper_limit="272804.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Levels of Sprifermin/FGF-18</title>
        <time_frame>Pre-dose at Week 0, 2 hours post-dose at Week 1 and 2 of Cycle 1, 2, 3 and 4 (each cycle is of 28 days)</time_frame>
        <population>Safety analysis set included all participants who received at least 1 dose of study treatment. Arm assignments for participants in Safety Set were based on actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received Placebo matched to Sprifermin as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Sprifermin (AS902330) 30 mcg/Placebo - 2 Cycles</title>
            <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Sprifermin (AS902330) 30 mcg- 4 Cycles</title>
            <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O4">
            <title>Sprifermin (AS902330) 100 mcg/Placebo (2 Cycles)</title>
            <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
          <group group_id="O5">
            <title>Sprifermin (AS902330) 100 mcg- 4 Cycles</title>
            <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Levels of Sprifermin/FGF-18</title>
          <population>Safety analysis set included all participants who received at least 1 dose of study treatment. Arm assignments for participants in Safety Set were based on actual treatment received.</population>
          <units>picogram/milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="107"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="111"/>
                <count group_id="O4" value="111"/>
                <count group_id="O5" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Serum levels of AS902330/FGF-18 could not be analyzed because the serum concentrations were not quantifiable, as serum sprifermin concentrations were below Lower Limit of Quantification (LLOQ). LLOQ=100 picogram/milliliter.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">Serum levels of AS902330/FGF-18 could not be analyzed because the serum concentrations were not quantifiable, as serum sprifermin concentrations were below Lower Limit of Quantification (LLOQ). LLOQ=100 picogram/milliliter.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">Serum levels of AS902330/FGF-18 could not be analyzed because the serum concentrations were not quantifiable, as serum sprifermin concentrations were below Lower Limit of Quantification (LLOQ). LLOQ=100 picogram/milliliter.</measurement>
                    <measurement group_id="O4" value="NA" spread="NA">Serum levels of AS902330/FGF-18 could not be analyzed because the serum concentrations were not quantifiable, as serum sprifermin concentrations were below Lower Limit of Quantification (LLOQ). LLOQ=100 picogram/milliliter.</measurement>
                    <measurement group_id="O5" value="NA" spread="NA">Serum levels of AS902330/FGF-18 could not be analyzed because the serum concentrations were not quantifiable, as serum sprifermin concentrations were below Lower Limit of Quantification (LLOQ). LLOQ=100 picogram/milliliter.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to 5 years. Participants were assessed for adverse events for the entire study.</time_frame>
      <desc>Adverse events are presented as per Safety Set.Arm assignments for participants in Safety Set were based on actual treatment received, such that 1participant assigned to Placebo arm who inadvertently received 30 mcg was included in Sprifermin 30mcg/placebo-2 Cycles arm for purpose of safety analysis. Similarly, 1 participant assigned to Sprifermin 30mcg/placebo-2 Cycles arm who inadvertently received 100 mcg was included in Sprifermin 100mcg/placebo-2 Cycles arm for purpose of safety analysis.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received Placebo matched to Sprifermin as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Sprifermin (AS902330) 30 mcg/Placebo - 2 Cycles</title>
          <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
        </group>
        <group group_id="E3">
          <title>Sprifermin (AS902330) 30 mcg- 4 Cycles</title>
          <description>Participants received Sprifermin 30 micrograms (mcg) as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
        </group>
        <group group_id="E4">
          <title>Sprifermin (AS902330) 100 mcg/Placebo (2 Cycles)</title>
          <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 0, 1, 2 in Cycle 1 and at week 52, 53, 54 in Cycle 3; and received placebo matched to Sprifermin once every week for 3 consecutive weeks for 2 alternative cycles, that is at week 26, 27, 28 in Cycle 2 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
        </group>
        <group group_id="E5">
          <title>Sprifermin (AS902330) 100 mcg- 4 Cycles</title>
          <description>Participants received Sprifermin 100 mcg as intra-articular injection once every week for 3 consecutive weeks for 4 cycles, that is at week 0, 1, 2 in Cycle 1; at week 26, 27, 28 in Cycle 2; at week 52, 53, 54 in Cycle 3 and at week 78, 79, 80 in Cycle 4 at interval of 6 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 21.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="41" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Toxic nodular goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Abdominal hernia obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Loose tooth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Parotid gland enlargement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cholangitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Skin injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Chondropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Vertebral foraminal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Benign pancreatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Benign salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Bladder transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour of the gastrointestinal tract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Diffuse large B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Fibroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Follicular thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Metastatic gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Papillary cystadenoma lymphomatosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Renal oncocytoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Arachnoid cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Chronic inflammatory demyelinating polyradiculoneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cubital tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Meningeal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Bladder neck obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Colpocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Uterine prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Vulvar dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Panniculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Removal of internal fixation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 21.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="106" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="109" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="106" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="107" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="30" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="57" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="55" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="54" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="33" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="27" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="109"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="111"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="111"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="109"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Communication Center</name_or_title>
      <organization>Merck KGaA, Darmstadt, Germany</organization>
      <phone>+49-6151-72-5200</phone>
      <email>service@emdgroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

